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Some interventions may include important spillover or dissemination effects between study participants
[2]. For example, vaccines, cash transfers, and education programs may exert a causal effect on
participants beyond those to whom individual treatment is assigned. In a recent paper, Buchanan et al.
[3] provide a causal definition of the “individual effect” of an intervention in networks of people who
inject drugs. This work builds on a definition of the “direct effect”, randomization design, and framework
for causal inference under interference introduced by Hudgens and Halloran [11]. Some researchers
have suggested that the “direct effect” may not always have a causal interpretation [7, 13, 15]. In this
short note, we discuss the interpretation of the individual effect when a spillover or dissemination effect
exists.
Potential outcomes and causal effects defined by Buchanan et al. [3]
Buchanan et al. [3] introduce potential outcome notation for the effect of an intervention on an unde-
sirable outcome (e.g. risk behavior, fatal overdose, HIV infection) among people who inject drugs. Let
Yki be an indicator for that outcome, where k = 1, . . . ,K is the cluster, and i = 1, . . . , nk is the indi-
vidual within that cluster. Let Xk be an indicator that cluster k is treated, meaning that a single cluster
member is the “index” participant who directly receives the intervention. In conformity with the causal
inference literature, we use the terms “treatment” and “intervention” interchangeably. Let Rki be the
indicator that individual i is the index, with exactly one index individual per cluster. Define the vector
of index indicators as Rk = (Rk1, . . . , Rknk). Define the individual potential outcome Yki(r, x), where
Rk = r is the vector of index subject indicators and Xk = x is the group-level treatment indicator.
Because
∑
iRki = 1 for all clusters k, the potential outcome notation Yki(r, x) reduces unambiguously
to Yki(r, x) where r = Rki indicates that individual i is the index; whenever Rki = 1, it is implicit that
Rkj = 0 for j 6= i. Buchanan et al. [3] defined the individual effect as
RDI = E[Yki(1, 1)− Yki(0, 1)],
the disseminated effect as
RDD = E[Yki(0, 1)− Yki(0, 0)],
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RDI = E[Yki(1, 1)− Yki(0, 1)]
i
vs
i
RDD = E[Yki(0, 1)− Yki(0, 0)]
i
vs
i
RDComp = E[Yki(1, 1)− Yki(0, 0)]
i
vs
i
Figure 1. Schematic illustration of the individual, disseminated, and composite effects defined by
Buchanan et al. [3] in a cluster of size 3. Cluster k is shown as a rectangle and subjects are shown
as circles, with subject i labeled. Gray shading indicates a treated index subject, and a hatched
pattern indicates a subject exposed to treatment via dissemination from a treated cluster member.
The individual effect RDI compares the potential outcome of subject i when treated with no dissemina-
tion from group members, versus the potential outcome of subject i when untreated with dissemination
from the treated index.
and the composite effect as
RDComp = E[Yki(1, 1)− Yki(0, 0)],
where expectation is with respect to the potential outcomes of individuals i across clusters k in the
study. The composite effect can be written as the sum of the individual and disseminated effects,
RDComp = RDI +RDD.
Meaning of the individual effect
The potential outcome notation of Buchanan et al. [3] implicitly encodes two distinct types of exposure
to the intervention for subject i in a treated cluster k. First, if subject i is the treated index (Rki = 1,
Xk = 1), then i receives exposure to the intervention via their own treatment, and no disseminated
exposure from another cluster member, because no other cluster members can be treated. Second, if
subject i is a non-index in a treated cluster (Rki = 0, Xk = 1), then i receives no direct exposure to the
intervention, but receives disseminated exposure from one treated index subject in their cluster. Figure
1 shows how the individual effect RDI contrasts potential outcomes by changing both of these types of
exposures simultaneously.
Buchanan et al. [3, Table 1, page 2450] interpret RDI as the “effect on persons directly receiving
an intervention beyond being in an intervention network”. When the outcome is undesirable and
E[Yik(0, 0)] ≥ E[Yik(0, 1)] ≥ E[Yik(1, 1)], RDI may indeed summarize the additional benefit of be-
ing an index, “beyond” that of experiencing disseminated effect. However, this monotonicity relation
may not always hold: an intervention with a strong disseminated effect may benefit untreated cluster
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members to a greater extent than those who personally receive treatment. In this case, the magni-
tude of the disseminated effect RDD would be greater than that of the composite effect RDComp, and
the interpretation of RDI as the additional benefit of being an index, “beyond” that of experiencing
disseminated effect, may not be meaningful.
A hypothetical intervention trial with a strong dissemination effect
One of the most effective interventions for reversing a potentially fatal opiate-related overdose is in-
tranasal or injection administration of naloxone during an overdose. Consider a hypothetical study of
clusters of people who inject drugs at risk of fatal opiate overdose, and an intervention that involves
dispensing a naloxone kit to one cluster member and training that individual in its administration. The
mechanism of action of this intervention in groups induces asymmetry in its effects: overdose involves
unconsciousness or incapacitation, so naloxone is rarely self-administered; instead, someone who has
it and has been trained in its use can avert another cluster member’s overdose.
Suppose that the outcome of interest is fatal overdose, and treatment involves receipt of a naloxone
kit from investigators and training in its use. A subject whose fellow cluster member is treated enjoys
a measure of protection against death due to overdose, because the treated subject can use their
naloxone kit to reverse their cluster member’s overdose, so RDD < 0. In contrast, the treated subject
may derive less benefit from their own treatment because they cannot use their own naloxone kit to
reverse their own overdose, except in rare cases [8]. It is possible, but perhaps less likely, that their
fellow cluster member not trained by investigators in its use might administer the treated subject’s
naloxone kit to the treated subject, should they experience an overdose, implying RDD < RDComp ≤ 0.
Clearly treatment is beneficial to any individual whose fellow cluster member receives it, and is either
beneficial or ineffective to individuals who only receive it themselves. However, the individual effect is
RDI = RDComp − RDD > 0, so treatment seems to be harmful to the subject who receives it. Of
course, naloxone is not harmful to anyone in this scenario; rather, the “individual effect” contrasts the
small (or nonexistent) beneficial effect of individual treatment (RDComp) against the larger beneficial
disseminated effect of treatment (RDD).
Discussion
The quantity RDI introduced by Buchanan et al. [3] is a well-defined statistical estimand. However,
RDI may be misleading because it does not measure the effect of the intervention on the individual
who would receive it, holding treatment to others constant. Instead, RDI contrasts the potential out-
come of an individual who receives treatment but no disseminated exposure with that of an individual
who receives no treatment but disseminated exposure from another subject. When the disseminated
effect is large compared to the composite effect, RDI can be positive (suggesting harm) even when
the intervention is beneficial to treated individuals and their fellow cluster members. Buchanan et al. [3,
Table 4, page 2455] found a similar pattern in their evaluation of the HPTN 037 trial intervention: the
individual effect on any risk behavior RDI is estimated to be null (ineffective), even though the dissem-
inated and composite effects were estimated to be negative (beneficial). Two additional examples of
substantial public health importance could show a similar pattern. Early access to antiretroviral ther-
apy (ART) among HIV positive individuals is known to improve health and helps prevent transmission
to HIV-negative partners [5, 6, 9, 10]. Likewise, pre-exposure prophylaxis (PrEP) among HIV nega-
tive individuals helps prevent HIV infection in treated individuals [1, 4, 14]. While these interventions
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are known to benefit treated individuals, and reduce HIV transmission within groups [12], a trial that
computed an “individual effect” by contrasting RDComp against RDD might under-estimate the benefit
conferred by these interventions to treated individuals.
When might the individual effect RDI be of scientific interest? First, resource constraints might neces-
sitate a policy in which a single subject (or a fixed number of subjects) is treated per cluster, so a trial
design that enforces this constraint may naturally reveal the quantity of interest. Second, RDI may be
of interest to investigators and research subjects because it summarizes the ethical trade-off in benefit
or harm experienced by treated versus untreated individuals. In the case of PrEP, these trade-offs might
involve the benefit of reduced HIV infection risk for all cluster members, versus potential medication side
effects for individuals treated with PrEP [14]. That is, RDI answers the question, “am I better off being
treated or untreated, when someone in my cluster is treated?” If investigators desire a measure of the
effect of an intervention on an individual subject while holding disseminated exposure constant, the
“composite” effect RDComp may be a more readily interpretable causal estimand.
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